• Mashup Score: 0

    In this video from Hawaiian Eye 2021, John A. Hovanesian, MD, FACS, discusses the importance of educating patients on the possibilities associated with premium lens implants.

    See more Ophthalmology news and videos at https://www.healio.com/news/ophthalmology

  • Mashup Score: 0

    Rachita Navara, MD, FACC, member of ACC’s Electrophysiology Section Leadership Council and cardiologist at UCSF Hospital in San Francisco breaks down atrial fibrillation, the most common heart rhythm disorder, for AFib Awareness Month 2021.
    #ACCEP #AFib #AFibAwareness #AFibAwarenessMonth

  • Mashup Score: 0

    Joslyn Crowe, executive director of the National Niemann-Pick Disease Foundation (NNPDF), describes the Niemann-Pick community’s reaction to the FDA denying the approval of arimoclomol for the treatment of Niemann-Pick Type C (NPC).

    NPC is a disabling neurogenetic disorder that has been diagnosed prenatally, neonatally, during childhood, and even into adulthood. This very rare genetic disorder is marked by progressive motor dysfunction and a highly variable symptom profile and onset of symptoms. It can result in the patient’s death soon after birth or manifest as a chronic disorder with symptoms worsening slowly over time.

    Following the news that the FDA sent a complete response letter (CRL) regarding arimoclomol, Ms. Crowe notes that the community was devastated. The degenerative nature of NPC, she says, does not allow patients to wait a long time for a drug approval. Thus, according to Ms. Crowe, the denial of arimoclomol is likely to lead to many unnecessary patient deaths.

    Though she does not know the FDA’s rationale, it is suspected that the FDA denied the approval based on “swallowing” being a domain in the 5-domain NPCCSS in the study data presented to the FDA. The study, which is ongoing, has a primary endpoint of change in the NPC disease severity based on the NPCCSS scores. Therefore, “swallowing” is directly connected to the primary endpoint which, Ms. Crowe, believes the FDA has a problem with. This is troublesome because a number of clinical trials in NPC, as well as other rare neurodegenerative disorders, use swallowing as part of their primary endpoint. This CRL thus may set a precedent that makes it near impossible for other NPC drugs to be approved.

    To stay up to date with the latest news in rare disease, sign up for our weekly newsletter here.

  • Mashup Score: 0

    To learn more about Dr. Zahka, please visit https://cle.clinic/3DZJtED

    It’s well known that exercise is an important way to keep your heart healthy. But how does this apply to children? Pediatric cardiologist Kenneth Zahka, MD, talks about the importance of exercise throughout childhood and how activity is a part of a child’s heart health.

    ▶Share this video with others: https://youtu.be/V9HERQD04qs

    ▶For more Health Essentials video podcasts:

    ▶Subscribe to learn more about Cleveland Clinic:
    https://www.youtube.com/user/ClevelandClinic?sub_confirmation=1

    Subscribe to our podcast 🎧
    Apple Podcasts: https://cle.clinic/podcastIOS
    Android: https://cle.clinic/Android
    SoundCloud: https://cle.clinic/soundcloud
    Spotify: https://cle.clinic/2AEPNlG

    #HealthEssentials #KidsHealth

  • Mashup Score: 0

    Bobbi Pineda, PhD, OTR/L, CNT, Assistant Professor at University of Southern California Chan Division of Occupational Science and Occupational Therapy, visits Brain Club to discuss neonatal therapy and the importance of sensory exposure.

    ▶Share this video with others: https://youtu.be/kFgxDacUFrs

    ▶For more videos from the Neonatal Brain Club Lecture Series, please visit https://www.youtube.com/playlist?list=PLMG0zKOgNqNmOsqvpETIRRGyHpJrYNenL

    ▶Subscribe to learn more about Cleveland Clinic:
    https://www.youtube.com/user/ClevelandClinic?sub_confirmation=1

  • Mashup Score: 0

    MPEROR-Preserved, the LOOP study, ablate-and-pace for AF, and salt substitute and stroke: John Mandrola, MD provides a first of two ESC reviews. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

    1 – HFpEF

    – EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough https://www.medscape.com/viewarticle/957405

    – Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038

    – Empagliflozin and Major Renal Outcomes in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMc2112411

    – Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2022190

    2 – AF Screening

    – LOOP Trial Undercuts Value of Long-term Continuous ECG Screening for Atrial Fibrillation https://www.medscape.com/viewarticle/957473

    – Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext

    – Subclinical Atrial Fibrillation and the Risk of Stroke https://www.nejm.org/doi/full/10.1056/nejmoa1105575

    3 – Ablate and Pace for AF and HF

    – APAF-CRT: ‘Ablate and Pace’ Cuts Mortality in Narrow-QRS HF, Permanent AF https://www.medscape.com/viewarticle/957467

    – A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS https://academic.oup.com/eurheartj/article/39/45/3999/5078460

    – AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial https://doi.org/10.1093/eurheartj/ehab569

    4 – Salt Substitute and Stroke

    – Salt Substitute Shows Clear Reduction in Stroke, CV Events, and Death https://www.medscape.com/viewarticle/957472

    – Effect of Salt Substitution on Cardiovascular Events and Death https://www.nejm.org/doi/full/10.1056/NEJMoa2105675

    Features:

    – Incremental, Not Monumental, Win for Empagliflozin in Heart Failure With Preserved Ejection Fraction https://www.medscape.com/viewarticle/957465

    – Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context https://www.medscape.com/viewarticle/957388

    – Lessons on AF Screening From the LOOP Study https://www.medscape.com/viewarticle/957512

    – Ablate-and-Pace Delivers a Huge Win for Those Sick With AF https://www.medscape.com/viewarticle/958033

    – Will the Positive Findings From the SSaSS Trial on Salt Substitution Silence the Salt Skeptics? https://www.medscape.com/viewarticle/957510

    You may also like:

    Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

    The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net

  • Mashup Score: 0

    Nina Shah, MD, of the University of California San Francisco (UCSF) Health talks about the upcoming data being presented focused on chimeric antigen receptor (CAR)-T cell therapy to treat patients with multiple myeloma at the American Society of Hematologists (ASH) Annual Meeting being held in Orlando, Florida.

    Multiple myeloma is a hematologic malignancy characterized by the expansion of malignant plasma cells in the bone marrow associated with excessive production of monoclonal immunoglobulins in blood and urine.

    A tremendous amount of research has greatly improved treatment options for individuals with multiple myeloma but this rare blood cancer remains an incurable condition. CAR-T cell therapy is a promising new treatment option in development for these patients. CAR-T cell therapy consists in infusing engineered T cells that carry a chimeric antigen receptor (CAR) on the cell membrane. The CAR is designed to recognize a specific molecule in a cancer cell and thereby creates a targeted T cell attack towards cancer cells.

    For more information about this and other rare blood disorders, visit https://checkrare.com/diseases/blood-diseases/

  • Mashup Score: 0

    Nina Shah, MD, hematologist-oncologist at the University of California San Francisco (UCSF) Health talks about the latest multiple myeloma data being presented at the American Society of Hematologists (ASH) Annual Meeting being held in Orlando, Florida.

    Multiple myeloma is a hematologic malignancy. It is characterized by the expansion of malignant plasma cells in the bone marrow associated with excessive production of monoclonal immunoglobulins in blood and urine. Individuals with multiple myeloma develop significant osteolytic bone lesions and have immunodeficiency that compromise their longevity and quality of life.

    While a tremendous amount of research has greatly improved treatment options for individuals with multiple myeloma, this rare blood cancer remains an incurable condition. Fortunately, continuing research, such as that presented at the latest ASH conference, is helping clinicians improve the way the manage their multiple myeloma patients.

    For more information about this and other rare blood disorders, visit https://checkrare.com/diseases/blood-diseases/

  • Mashup Score: 0

    Patient Testimonial: In 2017, John had a heart attack on Thanksgiving Day. He talks about finding out what it means to eat healthy, manage stress, and to keep learning about your condition. Taking steps to lower your LDL, or “bad” cholesterol, is not simply about the number. It’s about lowering the chance of a first or future heart attack or stroke. Learn more at https://www.CardioSmart.org/HighCholesterol.
    #CholesterolEducationMonth, #cholesterol, #ASCVD